|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our results show a significant association between the dopamine D2 receptor gene polymorphism Taq IA and SOS in PD.
|
15390060 |
2004 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The importance of dopamine D2 receptors (DRD2) for central nervous dopaminergic signalling makes variants in the DRD2 gene potential modulators of the risk or course of various behavioural, psychiatric or neurologic diseases (e.g. addiction, schizophrenia, Parkinson's disease).
|
19512960 |
2009 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Dopamine D2 receptor TaqIA and TaqIB polymorphisms in Parkinson's disease.
|
12722176 |
2003 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Previously, we found a significant association between the dopamine D2 receptor gene polymorphism Taq IA and sudden onset of sleep in patients with Parkinson disease.
|
16124668 |
2005 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Since genetic factors could play a role in determining the occurrence of these problems, the aim of the present study was to investigate whether possible functional polymorphisms among DRD2 and ANKK1 genes are associated with the risk of developing dyskinesia and motor fluctuations in Parkinson's disease patients.
|
23171335 |
2012 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
To investigate the association between Dopamine receptor D type 2 (DRD2) dinucleotide short tandem repeat (CA<sub>n</sub>-STR) and Dopamine receptor D type 3 (DRD3) Ser9Gly polymorphisms and the risk of PD, as well as the possible reasons for PD patients using different doses of DAs, we recruited 168 idiopathic PD patients and 182 controls.
|
27817855 |
2017 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease.
|
29434188 |
2018 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Thus our results do not support a role for the DRD2 locus to develop PD.
|
10515181 |
1999 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We tested for gender-specific interactions between smoking and genetic polymorphisms of monoamine oxidase B (MAO-B) intron 13 (G or A allele), monoamine oxidase A (MAO-A) EcoRV (Yor N allele), and dopamine D2 recepor (DRD2) Taq1B (B1 or B2 allele) in a case-control study of 186 incident idiopathic Parkinson's disease (PD) cases and 296 age- and gender-matched controls.
|
12428723 |
2002 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In the present study, we investigated this effect in Parkinson's disease (PD) patients carrying the DRD2 TaqIA A1 allelic variant.
|
17147698 |
2007 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Further, DRD2 variants have been implicated in Parkinson's disease (PD) and in iatrogenically-induced movement disorders, as well as in certain migraineurs.
|
11256581 |
2000 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We examined the relation between inhibitory ability (measured by the Stop Signal Task) and polymorphisms of COMT Val158Met and DRD2 C957T in patients with idiopathic PD.
|
24749760 |
2014 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Among non-Hispanic whites, homozygous carriers of Taq1A DRD2 (rs1800497) polymorphism had an increased risk of PD compared to homozygous wildtype carriers (OR=1.5, 95% CI 1.0-2.3).
|
21663922 |
2011 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Genotype combinations characterized by the presence of two variant genotypes on their corresponding loci revealed that four combinations of GSTT1 null and MnSOD(-9Val) or GST null and MAOB-G or CYP2E1*5B and MAO-B-AG or CYP2E1*5B and DRD2 (Taq1A-het) genotypes in the patients exhibited severalfold higher and significant association with risk to PD.
|
18327668 |
2008 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The DRD2 rs1800497 and DRD4 rs1800955 polymorphisms showed no association with PD.
|
21781348 |
2011 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The DRD3 (rs6280) polymorphism, but not DRD2 (Taq1A) or GRIN2B, influences younger PD age of onset in the US Caucasian population.
|
26627941 |
2016 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We conclude that the DRD2 TaqIA polymorphism alone has no pivotal role for interindividual variability of dopaminergic requirement in PD.
|
18175338 |
2008 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Genetic variation in the DRD2 gene may influence the risk of developing PD, thus confirming that the DRD2 gene is a susceptibility locus for PD.
|
10634251 |
2000 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients.
|
19396436 |
2009 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to evaluate a possible relationship between DRD2/ANKK1 (rs1800497) and SLC6A3/DAT1 (rs28363170) gene polymorphisms with the response to levodopa (L-DOPA)-therapy in patients with Parkinson's disease (PD).
|
30353564 |
2019 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In this study, we investigated the hypothesis that a TaqI repeat fragment length polymorphism in the dopamine D2 receptor gene may be associated with PD.
|
11104188 |
2000 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Human genetic studies also show a significant association of DRD2 polymorphisms with disorders including schizophrenia and Parkinson's disease.
|
29107444 |
2017 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Single nucleotide polymorphisms, rs2283265 and rs1076560, in the dopamine D2 receptor gene (DRD2) were found to be significantly associated with a favourable peak response to rasagiline at 12 weeks in early Parkinson's disease after controlling for multiple testing.
|
27190009 |
2016 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
This study identified apomorphine use and levodopa dosages between 500 and 1000 mg as non-genetic and the 15× DRD2 CA repeat allele as genetic determinants for the discontinuation of non-ergoline DA treatment in patients with PD.
|
19669131 |
2009 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The poorer cognitive performance in DRD2 <sup>957</sup> T/T carriers with PD occurred mainly in episodic memory and attention.
|
28869277 |
2018 |